Recombinant vectors based on the modified vaccinia ankara virus (MVA) as preventive and therapeutic vaccines against AIDS

• US 8,871,219 B2
• Filed: 07/25/2006
• Issued: 10/28/2014
• Est. Priority Date: 07/27/2005
• Status: Expired due to Fees

• Current Assignee: Consejo Superior de Investigaciones Científicas,
• Original Assignee: Consejo Superior de Investigaciones Científicas,
• Inventors: Heeney, Jonathan, Mooij, Petra, Gomez Rodriguez, Carmen Elena, Najera Garcia, Jose Luis, Jimenez Tentor, Victoria, Esteban Rodriguez, Mariano
• Primary Examiner(s): Humphrey, Louise
• Application Number:
  US11/989,425
• Publication Number:
  US 20100047276A1
• Time in Patent Office: 3,017 Days
• Field of Search: None
• US Class Current: 424/199.1
• CPC Class Codes: A61K 2039/5254 avirulent or attenuated
• CPC Class Codes: A61K 2039/5256 expressing foreign proteins
• CPC Class Codes: A61K 2039/5258 Virus-like particles
• CPC Class Codes: A61K 2039/545 characterised by the dose, timing or administration schedule
• CPC Class Codes: A61K 31/7088 Compounds having three or more nucleosides or nucleotides
• CPC Class Codes: A61K 39/12 Viral antigens
• CPC Class Codes: A61K 39/21 Retroviridae, e.g. equine infectious anemia virus
• CPC Class Codes: C07K 14/005 from viruses
• CPC Class Codes: C07K 2319/00 Fusion polypeptide
• CPC Class Codes: C12N 2710/24143 viral genome or elements thereof as genetic vector
• CPC Class Codes: C12N 2740/15022 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
• CPC Class Codes: C12N 2740/15034 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
• CPC Class Codes: C12N 2740/16034 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
• CPC Class Codes: C12N 2740/16122 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
• CPC Class Codes: C12N 2740/16222 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
• CPC Class Codes: C12N 2740/16322 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Abstract

Recombinant vectors which are based on the Modified Ankara Virus (MVA) as preventive and therapeutic vaccines against AIDS. The recombinant viruses contain sequences which are inserted at an MVA insertion site and enable simultaneous expression of antigens, a HIV-1 Env protein consisting of a gp120 protein lacking sequences corresponding to protein gp 41 and a chimeric fusion protein of Gag, Pol and Nef. These viruses are stable and can trigger immune responses against a large variety of antigens. Viruses having a chimeric protein from HIV-1 are suitable for the preparation of vaccines against AIDS.

Claims

1. A recombinant modified Vaccinia Ankara (MVA) vector comprising nucleotide sequences encoding a modified human immunodeficiency type 1 virus (HIV-1) Env protein and a HIV-1 Gag-Pol-Nef fusion protein, wherein the nucleotide sequence encoding the modified HIV-1 Env protein is SEQ ID NO:

15 or SEQ ID NO;

17, wherein the nucleotide sequence encoding the Env protein and the nucleotide sequence encoding the Gag-Pol-Nef fusion protein are under the control of identical promoters and are both inserted at the thymidine kinase locus of the vector so that the recombinant vector lacks the thymidine kinase gene.

2. The recombinant vector according to claim 1, wherein the nucleotide sequences are generated from natural isolates.

3. The recombinant vector according to claim 2, wherein the nucleotide sequence encoding the modified HIV-1 Env protein is generated by eliminating the entire sequence of the gp41 gene that naturally appears after the last nucleotide of the gp120 gene.

4. The recombinant vector according to claim 2, wherein the nucleotide sequence encodes a Gag-Pol-Nef fusion protein that is not proteolyzed by HIV protease.

5. The recombinant vector according to claim 2, wherein the identical promoters allow the expression of the proteins during both early and late stages of the MVA infection cycle.

6. The recombinant vector according to claim 5, wherein the identical promoters are synthetic pE/L promoters.

7. The recombinant vector according to claim 1, wherein the nucleotide sequence encoding the Env protein is modified to eliminate the natural sequence that appears after the last nucleotide of the gp120 gene, the nucleotide sequence encodes a Gag-Pol-Nef fusion protein that is not proteolyzed by HIV protease, and the promoters that control the expression of the Env protein and the Gag-Pol-Nef fusion protein are synthetic pE/L promoters.

8. The recombinant vector according to claim 7, wherein both the nucleotide sequence encoding the Env protein and the nucleotide sequence encoding the Gag-Pol-Nef fusion protein have been generated from natural B clade isolates.

9. The recombinant vector according to claim 8, wherein SEQ ID NO:

15 encodes the Env protein, gp120, from isolate BX08.

10. The recombinant vector according to claim 8, wherein the nucleotide sequence encoding said fusion protein is SEQ ID NO:

16 and is generated from isolate IIIB.

11. The recombinant vector according to claim 7, wherein both the nucleotide sequence encoding the Env protein and the nucleotide sequence encoding the Gag-Pol-Nef fusion protein are generated from natural C clade isolates.

12. The recombinant vector according to claim 11, wherein the nucleotide sequence encoding the Env protein is SEQ ID NO:

17 and is generated from isolate CN54.

13. The recombinant vector according to claim 11, wherein the nucleotide sequence encoding the fusion protein is SEQ ID NO:

18 and is generated from isolate CN54.

14. The recombinant vector according to claim 12, wherein the nucleotide sequence encoding the Env protein is SEQ ID NO:

17 from isolate CN54 and the nucleotide sequence encoding the fusion protein is SEQ ID NO;

18 from isolate CN54.

15. A composition comprising a recombinant vector according to claim 1.

16. The composition according to claim 15 for administration to a subject to provoke or reinforce an immune response against HIV.

17. The composition according to claim 15 for administration to a subject as part of an immunization protocol in which a first dose is administered to trigger the immune response and one or more doses are administered subsequently to boost the initial immune response.

18. The composition according to claim 17, containing:

(1) a first recombinant vector comprising SEQ ID NO;

15 encoding the Env protein, gp120, from isolate BX08, and SEQ ID NO;

16 encoding the Gag-Pol-Nef fusion protein from isolate IIIB, and (2) a second recombinant vector comprising SEQ ID NO;

17 encoding the Env protein, gp120, from isolate CN54, and SEQ ID NO;

18 encoding the Gag-Pol-Nef fusion protein from isolate CN54.

19. A method comprising administering to a subject the vector according to claim 1 to trigger and/or boost an immune response against HIV.

20. The method according to claim 19, comprising administering to the subject a single dose of the vector to trigger an immune response against HIV.

21. The method according to claim 19, comprising administering to the subject more than one dose of the vector to trigger and boost an immune response against HIV.

22. A method comprising administering to a subject the vector according to claim 8 to trigger and/or boost an immune response against HIV.

23. A method comprising administering to a subject the vector according to claim 11 to trigger and/or boost an immune response against HIV.

24. A method comprising administering to a subject the vector according to claim 13 to trigger and/or boost an immune response against HIV.

25. A method comprising administering to a subject the vector according to claim 10 to trigger and/or boost an immune response against HIV.

26. A method comprising administering to a subject the vector according to claim 12 to trigger and/or boost an immune response against HIV.

27. A method comprising administering to a subject the vector according to claim 14 to trigger and/or boost an immune response against HIV.

28. The method according to claim 21, comprising administering to the subject one or more booster doses of the vector.

29. The method according to claim 28, comprising administering to the subject a third dose comprising the vector.

30. The method according to claim 28, comprising administering to the subject a fourth dose comprising the vector.

31. A composition comprising the recombinant vector of claim 8 for administration to a subject to provoke or reinforce an immune response against an HIV clade B virus.

32. The composition according to claim 31 for administration to a subject to provoke or reinforce an immune response against an HIV BX08 isolate.

33. A composition comprising the recombinant vector of claim 11 for administration to a subject to provoke or reinforce an immune response against an HIV clade B virus.

34. The composition according to claim 33 for administration to a subject to provoke or reinforce an immune response against an HIV CN54 isolate.

35. The composition according to claim 18 for administration to a subject to provoke or reinforce an immune response against an HIV clade B virus and/or an HIV clade C virus.